P Biron

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
  2. ncbi request reprint Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
    P Biron
    Centre Leon Berard, Lyon, France
    Bone Marrow Transplant 41:555-62. 2008
  3. ncbi request reprint [How to manage medical imaging performed outside the hospital?]
    P Biron
    Departement de Medecine Oncologique, Chef de Projet Dossier Patient Informatisé, Centre régional Léon Bérard, France
    J Radiol 89:521-3. 2008
  4. ncbi request reprint Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)
    P Biron
    Centre régional Léon Bérard, Lyon, France
    J Antimicrob Chemother 42:511-8. 1998
  5. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
  6. ncbi request reprint The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group
    J Blay
    PARMA Cooperative Group with Fédération Nationale des Centres de Lutte Contre le Cancer FNCLCC, Dutch Haemato Oncology Working Party HOVON, European Organization for Research and Treatment of Cancer EORTC, Lyon, France
    Blood 92:3562-8. 1998
  7. pmc Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
    I Ray Coquard
    , Lyon, France
    Br J Cancer 85:816-22. 2001
  8. doi request reprint Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    H Ghesquieres
    Department of Hematology, Centre Leon Berard, Universite de Lyon, 28 rue Laennec, Lyon, France
    Ann Oncol 21:842-50. 2010
  9. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults
    J Y Blay
    Centre Léon Bérard and Hôpital Edouard Herriot, Lyon, France
    J Clin Oncol 18:3643-50. 2000
  10. ncbi request reprint High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
    J Y Blay
    Centre Leon Berard, Lyon, France
    J Clin Oncol 16:864-71. 1998

Detail Information

Publications33

  1. pmc Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region
    Antoine Lurkin
    Centre Leon Berard, Lyon, France
    BMC Cancer 10:150. 2010
    ..We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)...
  2. ncbi request reprint Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer
    P Biron
    Centre Leon Berard, Lyon, France
    Bone Marrow Transplant 41:555-62. 2008
    ..8) and 22.9 versus 22.3 months median time to relapse in the intensification and observation arms, respectively. In this randomized trial, HDC with CHUT improved DFS but not OS, corroborating findings from earlier trials...
  3. ncbi request reprint [How to manage medical imaging performed outside the hospital?]
    P Biron
    Departement de Medecine Oncologique, Chef de Projet Dossier Patient Informatisé, Centre régional Léon Bérard, France
    J Radiol 89:521-3. 2008
  4. ncbi request reprint Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patients with short duration neutropenia. CEMIC (Study Group of Infectious Diseases in Cancer)
    P Biron
    Centre régional Léon Bérard, Lyon, France
    J Antimicrob Chemother 42:511-8. 1998
    ..001). Cefepime monotherapy was as effective as, and better tolerated than, imipenem-cilastatin in the empirical treatment of fever during short duration neutropenia...
  5. ncbi request reprint Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens
    I Ray-Coquard
    Centre Leon Berard, Lyon, France
    Cancer 82:134-40. 1998
    ..v.) infusion, and vinorelbine (VNB) was delivered at a dose of 6 mg i.v. bolus followed by VNB, 6 mg/m2/day, in continuous i.v. infusion (Days 1-5) every 21 days...
  6. ncbi request reprint The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group
    J Blay
    PARMA Cooperative Group with Fédération Nationale des Centres de Lutte Contre le Cancer FNCLCC, Dutch Haemato Oncology Working Party HOVON, European Organization for Research and Treatment of Cancer EORTC, Lyon, France
    Blood 92:3562-8. 1998
    ....
  7. pmc Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas
    I Ray Coquard
    , Lyon, France
    Br J Cancer 85:816-22. 2001
    ..In conclusion, poor performance status and lymphopenia identify a subgroup of patients at high risk for early death after chemotherapy...
  8. doi request reprint Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
    H Ghesquieres
    Department of Hematology, Centre Leon Berard, Universite de Lyon, 28 rue Laennec, Lyon, France
    Ann Oncol 21:842-50. 2010
    ..This prospective multicentric phase II study aimed to confirm the results of the C5R protocol of high-dose methotrexate (MTX)-based chemotherapy (CT) for immunocompetent primary central nervous system lymphoma...
  9. ncbi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation for advanced soft tissue sarcoma in adults
    J Y Blay
    Centre Léon Bérard and Hôpital Edouard Herriot, Lyon, France
    J Clin Oncol 18:3643-50. 2000
    ..The role of high-dose chemotherapy (HDCT) with hematopoietic stem-cell support in this disease is not established...
  10. ncbi request reprint High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series
    J Y Blay
    Centre Leon Berard, Lyon, France
    J Clin Oncol 16:864-71. 1998
    ..The impact of treatment options on survival and late neurologic toxicity was investigated in a series of patients with primary cerebral lymphoma (PCL) and no known cause of immunosuppression...
  11. ncbi request reprint Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer
    J Y Blay
    Centre Leon Berard, Lyon, France
    Ann Oncol 11:39-44. 2000
    ..Primary cerebral non-Hodgkin's lymphomas (NHL) in immunocompetent patients (PCL) are located exclusively in the central nervous system, the eye, or meninges. Clinical management of these patients remains controversial...
  12. ncbi request reprint A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy
    J Y Blay
    Centre L BERARD, Lyon, France
    Blood 92:405-10. 1998
    ..1) from those calculated in the model. This risk index could be useful to identify patients at high risk for chemotherapy-induced thrombocytopenia requiring platelet transfusions...
  13. pmc Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy
    I Ray-Coquard
    Centre L Bérand, Lyon, France
    Br J Cancer 88:181-6. 2003
    ..The 'day 1' model identifies a small population of patients at high risk for FN, but has a lower sensitivity than the day 5 model...
  14. ncbi request reprint Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution
    M Michallet
    Service d Hématologie de l Hôpital Edouard Herriot, Lyon, France
    Exp Hematol 28:858-70. 2000
    ....
  15. ncbi request reprint [Necessary harmonization of health cost assessment. Autologous peripheral blood progenitor cell transplantation in France]
    L Perrier
    GRESAC, Unité CNRS 5823, Centre Leon Berard, 28, rue Laennec, 69373 Lyon Cedex 08, France
    Rev Epidemiol Sante Publique 50:393-403. 2002
    ..The purpose of this study was to determine to what extent methods used to assess health cost affect the total cost of a therapeutic procedure...
  16. doi request reprint Influenza vaccination in patients with haematologic malignancies: analysis of practices in 200 patients in a single center
    F Lachenal
    Centre Leon Berard, Department of Haematology, 28, rue Laennec, 69008 Lyon, France
    Bull Cancer 97:E33-6. 2010
    ..The aim of this study was to analyse practices and factors influencing vaccination in a single centre, in the light of recent literature data...
  17. doi request reprint A risk model for severe anemia to select cancer patients for primary prophylaxis with epoetin alpha: a prospective randomized controlled trial of the ELYPSE study group
    I Ray-Coquard
    Department of Medical Oncology, Léon Bérard Comprehensive Cancer Center, University of Lyon, and EA 4128 SIS Individu Santé, Société, Lyon, France
    Ann Oncol 20:1105-12. 2009
    ....
  18. ncbi request reprint Evaluation of core needle biopsy as a substitute to open biopsy in the diagnosis of soft-tissue masses
    I Ray-Coquard
    Centre Leon Berard, 28 rue Laennec, Lyon 69008, France
    Eur J Cancer 39:2021-5. 2003
    ..CNB is accurate, not misleading for s-t-M diagnosis, avoids open biopsy complications, and allows one-surgery or neo-adjuvant chemotherapy planning when combined with appropriate imaging...
  19. ncbi request reprint Importance of surgery as salvage treatment after high dose chemotherapy failure in germ cell tumors
    A Flechon
    Departments of Medical Oncology and Surgery, Centre Leon Berard, Lyon, France
    J Urol 165:1920-6. 2001
    ..The survival of patients with germ cell cancer after failed high dose chemotherapy is poor. We retrospectively reviewed the various treatment choices in this situation...
  20. ncbi request reprint The Rhône-Alpes health platform
    T Durand
    Centre Leon Berard, Lyon, France
    Methods Inf Med 46:451-7. 2007
    ..The health platform called SIS-RA is used through a Web interface. An iconic interface is dedicated to the platform and presents information in a unique way for all users...
  21. ncbi request reprint Association of CD4 lymphopenia with survival in patients with advanced cancer
    J Peron
    Centre Leon Berard, Lyon, France The Royal Marsden Hospital, Sutton, United Kingdom Besançon University Hospital, Besancon, France Centre Leon Berard, Lyon, France
    J Clin Oncol 29:e21145. 2011
    ..We report here the impact of CD4 lyp on patient survival after 10 years...
  22. pmc An information retrieval system for computerized patient records in the context of a daily hospital practice: the example of the Léon Bérard Cancer Center (France)
    P Biron
    Leon Berard Cancer Center, Lyon, France
    Appl Clin Inform 5:191-205. 2014
    ..This tool was integrated into the hospital information system by the IT department having been granted full autonomy to improve the system...
  23. ncbi request reprint Sarcomas and malignant phyllodes tumours of the breast--a retrospective study
    C Confavreux
    Centre régional de lutte contre le cancer Léon Bérard, 28 rue Laennec, 69008 Lyon, France
    Eur J Cancer 42:2715-21. 2006
    ..They are composed of a connective tissue stroma and epithelial elements. Pathological presentation ranges from grade I to malignant phyllodes tumours (grade III) where the stromal component clearly exhibits a sarcoma pattern...
  24. ncbi request reprint [High-dose chemotherapy in soft tissue sarcomas of adults]
    I Ray-Coquard
    , 28, rue Laennec, 69008 Lyon
    Bull Cancer 88:858-62. 2001
    ..Phase III studies are required to confirm that survival may be improved by HDCT in subgroups of patients with ASTS...
  25. ncbi request reprint Non-Hodgkin's lymphoma of the testis: a retrospective study of 84 patients treated in the French anticancer centres
    J L Lagrange
    Radiation Therapy Group of the Federation of Cancer Centers, Paris, France
    Ann Oncol 12:1313-9. 2001
    ..Systemic adjuvant chemotherapy should be discussed because of the high recurrence rate. Inclusion of these cases in large co-operative prospective studies is recommended...
  26. pmc A phase I/II study of 4 monthly courses of high-dose cyclophosphamide and thiotepa for metastatic breast cancer patients
    T Bachelot
    Département de Cancérologie Médicale Centre Léon Bérard, 28 rue Laennec, 69373 Lyon Cedex, France
    Br J Cancer 87:1079-85. 2002
    ..Three patients were alive, free of disease 30 months after completion of the study. Such therapy allows for high-dose intensity and high cumulative doses on a short period of time with manageable toxicity...
  27. ncbi request reprint A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours
    J L Pico
    Institut Gustave Roussy, Villejuif, France
    Ann Oncol 16:1152-9. 2005
    ..Incomplete remission or relapse from first-line chemotherapy has poor prognosis in male germ cell tumour patients. This phase III randomised trial compares conventional salvage to high-dose-intensification chemotherapy...
  28. doi request reprint High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a quality-adjusted survival analysis
    Patricia Marino
    INSERM, Unit Research 379, Marseilles, France
    Am J Clin Oncol 31:117-24. 2008
    ..We evaluated the trade-offs between toxicity, relapse, and costs using a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis...
  29. pmc Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials
    Nathalie Mourad
    INSERM U728, Paris, France
    Blood 111:4463-70. 2008
    ..It portends a poor prognosis even when treated intensively. However, AITL is not always lethal with 30% of patients alive at 7 years...
  30. ncbi request reprint High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL)
    E Jabbour
    Departement de Medecine, Institut Gustave Roussy, Villejuif, France
    Leukemia 20:814-9. 2006
    ..The Ann Arbor stage, age and serum lactate dehydrogenase level did not influence outcomes. This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement...
  31. ncbi request reprint A phase II trial of rituximab as adjuvant to intensive sequential chemotherapy in patients under 60 years with untreated poor-prognosis diffuse large B-cell lymphoma
    D Coso
    Department of Hematology, Cancer Center Institut J Paoli I Calmettes, Marseille Cedex, France
    Bone Marrow Transplant 38:217-22. 2006
    ..These data suggest that rituximab after HDT is feasible. Both complete remission rate and survival curves compare favorably with the poor outcome usually observed in high-risk DLBCL patients managed with HDT without rituximab...
  32. ncbi request reprint Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP)
    S Culine
    CRLC Val d Aurelle, Montpellier, France
    Ann Oncol 18:917-24. 2007
    ..High cure rates are expected in good-risk metastatic nonseminomatous germ-cell tumor (NSGCT) patients with bleomycin, etoposide and cisplatin...
  33. ncbi request reprint Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of
    J P Lotz
    Department of Medical Oncology, Hopital Tenon, Paris, France
    Ann Oncol 16:411-8. 2005
    ..High-dose chemotherapy (HD-CT) is able to circumvent platinum resistance of resistant/refractory germ-cell tumors (GCTs), but expectancy of cure remains low. New strategies are needed with new drugs and a sequential approach...